Search

Your search keyword '"Reboli, A.C."' showing total 10 results
Start Over Author "Reboli, A.C."
10 results on '"Reboli, A.C."'

1. Clinical Research In The Lay Press: Irresponsible Journalism Raises A Huge Dose Of Doubt

Author

Anaissie, E.J, Segal, B.H, Graybill, J.R, Arndt, C, Perfect, J.R, Kleinberg, M, Pappas, P, Benjamin, D, Rubin, R, Aberg, J.A, Adderson, E.E, Adler-Shohet, F.C, Akan, H, Akova, M, Almyroudis, N.G, Alexander, B.D, Andes, D, Arrieta, A, Baddley, J.W, Barron, M.A, Belzberg, H, Boucher, H.W, Boyce, T.G, Casadevall, A, Chandrasekar, P.H, Cleary, J.D, Cordonnier, C, Cornely, O.A, Cuenca-Estrella, M, Daly, J.S, Daoura, N, Denning, D.W, DePauw, B, De Repentigny, L, Dignani, M.C, Dismukes, W.E, Donnelly, J.P, Donowitz, G.R, Dupont, B, Drusano, G, Ellis, M, Espinel-Ingroff, A, Fishman, J.A, Fleming, R, Forrest, G, Ghannoum, M, Goldman, M, Grazziutti, M, Greene, J.H, Greenberg, R.N, Gubbins, P.O, Hadley, S, Herbrecht, R, Hiemenz, J.W, Hope, W, Hospenthal, D.R, Husain, S, Ito, J.I, Jacobson, R.M, Johnson, M, Keating, M.R, Kett, D.H, Knapp, K, Kontoyiannis, D.P, Krcmery, V.C, Larsen, R, Laverdiere, M, Ljungman, P, Lortholary, O, Maertens, J, Marriott, D, Mattiuzzi, G, McGinnis, M.R, Morris, M, Nucci, M, Odds, F.C, Pankey, G.A, Patterson, T, Pfaller, M, Razonable, R.R, Reboli, A.C, Rinaldi, M.G, Roberts, G.D, Rodriguez Tudela, J.L, Rotstein, C, Ruhnke, M, Schuster, M, Shoham, S, Sia, I.G, Siebel, N, Silviera, F, Singh, N, Sobel, J, Solomkin, J.S, Sorrell, T.C, Steinbach, W.J, Temesgen, Z, Tortorano, A, Vartivarian, S, Verweij, P, Viscoli, C, Viviani, M.A, Walker, R.C, Wheat, J.L, Wiley, J, Williamson, P, Wingard, J.R, Yu, V.L, Zaoutis, T., and İç Hastalıkları

Published
2006

2. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

Author

Andes, D.R., Safdar, N., Baddley, J.W., Playford, G., Reboli, A.C., Rex, J.H., Sobel, J.D., Pappas, P.G., Kullberg, B.J., Andes, D.R., Safdar, N., Baddley, J.W., Playford, G., Reboli, A.C., Rex, J.H., Sobel, J.D., Pappas, P.G., and Kullberg, B.J.

Abstract

1 april 2012, Item does not contain fulltext, BACKGROUND: Invasive candidiasis (IC) is an important healthcare-related infection, with increasing incidence and a crude mortality exceeding 50%. Numerous treatment options are available yet comparative studies have not identified optimal therapy. METHODS: We conducted an individual patient-level quantitative review of randomized trials for treatment of IC and to assess the impact of host-, organism-, and treatment-related factors on mortality and clinical cure. Studies were identified by searching computerized databases and queries of experts in the field for randomized trials comparing the effect of >/=2 antifungals for treatment of IC. Univariate and multivariable analyses were performed to determine factors associated with patient outcomes. RESULTS: Data from 1915 patients were obtained from 7 trials. Overall mortality among patients in the entire data set was 31.4%, and the rate of treatment success was 67.4%. Logistic regression analysis for the aggregate data set identified increasing age (odds ratio [OR], 1.01; 95% confidence interval [CI], 1.00-1.02; P = .02), the Acute Physiology and Chronic Health Evaluation II score (OR, 1.11; 95% CI, 1.08-1.14; P = .0001), use of immunosuppressive therapy (OR, 1.69; 95% CI, 1.18-2.44; P = .001), and infection with Candida tropicalis (OR, 1.64; 95% CI, 1.11-2.39; P = .01) as predictors of mortality. Conversely, removal of a central venous catheter (CVC) (OR, 0.50; 95% CI, .35-.72; P = .0001) and treatment with an echinocandin antifungal (OR, 0.65; 95% CI, .45-.94; P = .02) were associated with decreased mortality. Similar findings were observed for the clinical success end point. CONCLUSIONS: Two treatment-related factors were associated with improved survival and greater clinical success: use of an echinocandin and removal of the CVC.

Published
2012

3. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Author

Pappas, P.G., Kauffman, C.A., Andes, D., Benjamin Jr., D.K., Calandra, T, Edwards, J.E., Filler, S.G., Fisher, J.F., Kullberg, B.J., Ostrosky-Zeichner, L., Reboli, A.C., Rex, J.H., Walsh, T.J., Sobel, J.D., Pappas, P.G., Kauffman, C.A., Andes, D., Benjamin Jr., D.K., Calandra, T, Edwards, J.E., Filler, S.G., Fisher, J.F., Kullberg, B.J., Ostrosky-Zeichner, L., Reboli, A.C., Rex, J.H., Walsh, T.J., and Sobel, J.D.

Abstract

Contains fulltext : 79640.pdf (publisher's version ) (Closed access), Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. Since 2004, several new antifungal agents have become available, and several new studies have been published relating to the treatment of candidemia, other forms of invasive candidiasis, and mucosal disease, including oropharyngeal and esophageal candidiasis. There are also recent prospective data on the prevention of invasive candidiasis in high-risk neonates and adults and on the empiric treatment of suspected invasive candidiasis in adults. This new information is incorporated into this revised document.

Published
2009

4. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.

Author

Anaissie, E., Segal, B.H., Graybill, J.R., Arndt, C., Perfect, J.R., Kleinberg, M., Pappas, P.G., Benjamin, D., Rubin, R., Aberg, J.A., Adderson, E.E., Adler-Shohet, F.C., Akan, H., Akova, M., Almyroudis, N.G., Alexander, B.D., Andes, D., Arrieta, A., Baddley, J.W., Barron, M.A., Belzberg, H., Boucher, H.W., Boyce, T.G., Casadevall, A., Chandrasekar, P.H., Cleary, J.D., Cordonnier, C., Cornely, O.A., Cuenca-Estrella, M., Daly, J.S., Daoura, N., Denning, D.W., Pauw, B.E. de, Repentigny, L. de, Dignani, M.C., Dismukes, W.E., Donnelly, J.P., Donowitz, G., Dupont, B., Drusano, G., Ellis, M., Espinel-Ingroff, A., Fishman, J.A., Fleming, R., Forrest, G., Ghannoum, M.A., Goldman, M, Grazziutti, M., Greene, J.N., Greenberg, R.N., Gubbins, P.O., Hadley, S., Herbrecht, R., Hiemenz, J.W., Hope, W., Hospenthal, D.R., Husain, S., Ito, J.I., Jacobson, R.M., Johnson, M., Keating, M.R., Kett, D.H., Knapp, K., Kontoyiannis, D.P., Krcmery, V., Larsen, R., Laverdiere, M., Ljungman, P., Lortholary, O., Maertens, J., Marriott, D., Mattiuzzi, G., McGinnis, M.R., Morris, M., Nucci, M., Odds, F.C., Pankey, G.A., Patterson, T., Pfaller, M., Razonable, R.R., Reboli, A.C., Rinaldi, M.G., Roberts, G.D., Rodriguez-Tudela, J.L., Rotstein, C., Ruhnke, M., Schuster, M., Shoham, S., Sia, I.G., Siebel, N., Silviera, F, Singh, N., Sobel, J., Solomkin, J.S., Sorrell, T.C., Steinbach, W.J., Temesgen, Z., Tortorano, A., Vartivarian, S., Anaissie, E., Segal, B.H., Graybill, J.R., Arndt, C., Perfect, J.R., Kleinberg, M., Pappas, P.G., Benjamin, D., Rubin, R., Aberg, J.A., Adderson, E.E., Adler-Shohet, F.C., Akan, H., Akova, M., Almyroudis, N.G., Alexander, B.D., Andes, D., Arrieta, A., Baddley, J.W., Barron, M.A., Belzberg, H., Boucher, H.W., Boyce, T.G., Casadevall, A., Chandrasekar, P.H., Cleary, J.D., Cordonnier, C., Cornely, O.A., Cuenca-Estrella, M., Daly, J.S., Daoura, N., Denning, D.W., Pauw, B.E. de, Repentigny, L. de, Dignani, M.C., Dismukes, W.E., Donnelly, J.P., Donowitz, G., Dupont, B., Drusano, G., Ellis, M., Espinel-Ingroff, A., Fishman, J.A., Fleming, R., Forrest, G., Ghannoum, M.A., Goldman, M, Grazziutti, M., Greene, J.N., Greenberg, R.N., Gubbins, P.O., Hadley, S., Herbrecht, R., Hiemenz, J.W., Hope, W., Hospenthal, D.R., Husain, S., Ito, J.I., Jacobson, R.M., Johnson, M., Keating, M.R., Kett, D.H., Knapp, K., Kontoyiannis, D.P., Krcmery, V., Larsen, R., Laverdiere, M., Ljungman, P., Lortholary, O., Maertens, J., Marriott, D., Mattiuzzi, G., McGinnis, M.R., Morris, M., Nucci, M., Odds, F.C., Pankey, G.A., Patterson, T., Pfaller, M., Razonable, R.R., Reboli, A.C., Rinaldi, M.G., Roberts, G.D., Rodriguez-Tudela, J.L., Rotstein, C., Ruhnke, M., Schuster, M., Shoham, S., Sia, I.G., Siebel, N., Silviera, F, Singh, N., Sobel, J., Solomkin, J.S., Sorrell, T.C., Steinbach, W.J., Temesgen, Z., Tortorano, A., and Vartivarian, S.

Abstract

Contains fulltext : 50792.pdf (publisher's version ) (Open Access)

Published
2006

5. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving Broad-spectrum antibacterial therapy: A randomized, controlled trial

Author

Boogaerts, M., Winston, D.J., Bow, E.J., Garber, G., Reboli, A.C., Schwarer, A.P., Novitzky, N., Boehme, A., Chwetzoff, E., de Beule, K., Phillips, E., Boogaerts, M., Winston, D.J., Bow, E.J., Garber, G., Reboli, A.C., Schwarer, A.P., Novitzky, N., Boehme, A., Chwetzoff, E., de Beule, K., and Phillips, E.

Abstract

Prolonged neutropenia is a major risk factor for invasive fungal infection (1–6). The incidence among neutropenic patients with cancer who are receiving intensive cytotoxic therapy ranges from 2% to 47%, depending on other concomitant risk factors (7). Mortality rates range from 35% to 90% (8). Fever may be the only clinical sign of infection, and definitive diagnosis is often problematic. Empirical therapy with amphotericin B deoxycholate reduces the relative risk for documented infection by 50% to 80% and overall mortality rates by 23% to 45% (1–2, 9–10). This practice is now standard in neutropenic patients with cancer who have persistent fever that does not respond to 3 to 7 days of treatment with broad-spectrum antibiotics (11).

Published
2001

7. Failure of systemic empiric antifungal therapy to prevent candidemia in neutropenic cancer patients

Author

Reboli, A.C. and Blumberg, E.

Subjects
Fungal antigens -- Health aspects, Neutropenia -- Complications and side effects -- Prevention, Candida -- Prevention -- Health aspects
Abstract

AUTHORS: A.C. Reboli and E. Blumberg. Philadelphia, Pennsylvania. According to the authors' abstract of a presentation to the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, held September 29 - [...]

Published
1991

8. An Outbreak of Burkholderia cepacia Lower Respiratory Tract Infection Associated With Contaminated Albuterol Nebulization Solution

Author

Reboli, A.C., Koshinski, R., Arias, K., Marks-Austin, K., Stieritz, D., and Stull, T.L.

Abstract

AbstractAn outbreak of Burkholderia cepacialower respiratory tract colonization and infection occurred in the adult intensive-care units in various geographic locations throughout our hospital. Forty-four patients became colonized or infected over an 11-month period, whereas B cepaciahad been isolated from only 13 patients in the preceding 48 months. Environmental cultures revealed the source to be extrinsically contaminated albuterol nebulization solution. Polymerase chain reaction-ribotyping confirmed the genetic relatedness of the B cepaciapatient isolates and the contaminated albuterol. After extensive infection control training for the respiratory therapy staff, including attention to nebulization technique, washing and drying the nebulizer cup, and good handwashing, there have not been any new cases.

Published
1996
Full Text
View/download PDF

9. Protease inhibitor-induced lipodystrophy

Author

Williamson, K., Reboli, A.C., and Manders, S.M.

Abstract

development of lipodystrophy as evidenced by central obesity, ''moon facies,'' and a ''buffalo hump'' is a classical feature of Cushing's disease. Recently an association of ''lipodystrophy'' with the use of protease inhibitors has been reported. We describe a patient with lipodystrophy secondary to protease inhibitor therapy for HIV infection. (J Am Acad Dermatol 1999;40:635-6.)

Published
1999
Full Text
View/download PDF

10. Itraconazole and Amphotericin B To Treat Fungal Infections in Patients with Cancer Who Are Receiving Chemotherapy.

Author

Boogaerts, M., Winston, D.J., Bow, E.J., Garber, G., Reboli, A.C., Schwarer, A.P., Novitzky, N., Boehme, A., Chwetzoff, E., and DeBeule, K.

Subjects
COMMUNICABLE disease treatment, MYCOSES, AMPHOTERICIN B, CHEMOTHERAPY complications, DRUG side effects
Abstract

Focuses on the use of itraconazole and amphotericin B for treating fungal infections in patients with cancer who are receiving chemotherapy. Occurrence of treatment failure due to progressive fungal infection; Influence of chemotherapy on the susceptibility to infection; Side effects of the treatment.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results